In vivo generation of engineered CAR T cells can reduce fibrosis and restore cardiac function after heart injury

By | January 7, 2022
A novel immunotherapy strategy using in vivo generation of transient engineered chimeric antigen receptor (CAR) T cells, through the delivery of modified mRNA, can reduce fibrosis and restore cardiac function in a mouse model of heart failure, researchers report.